Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | PRLD |
---|---|---|
09:32 ET | 616 | 4.04 |
09:54 ET | 100 | 3.99 |
09:56 ET | 1951 | 3.855 |
09:57 ET | 4017 | 3.905 |
09:59 ET | 300 | 3.99 |
10:08 ET | 500 | 3.97 |
10:21 ET | 500 | 3.96 |
10:24 ET | 100 | 3.96 |
11:27 ET | 400 | 3.935 |
12:05 ET | 300 | 3.9 |
12:09 ET | 3478 | 3.99 |
12:12 ET | 5984 | 3.92 |
12:14 ET | 6584 | 3.93 |
01:10 ET | 132 | 3.9 |
01:19 ET | 955 | 3.875 |
01:26 ET | 400 | 3.84 |
01:48 ET | 100 | 3.82 |
01:55 ET | 200 | 3.8 |
02:02 ET | 600 | 3.78 |
02:18 ET | 1490 | 3.75 |
02:38 ET | 200 | 3.75 |
02:47 ET | 711 | 3.73 |
02:58 ET | 500 | 3.745 |
03:05 ET | 2941 | 3.72 |
03:07 ET | 400 | 3.69 |
03:12 ET | 500 | 3.7112 |
03:20 ET | 100 | 3.7 |
03:21 ET | 100 | 3.7 |
03:23 ET | 200 | 3.72 |
03:27 ET | 100 | 3.7 |
03:30 ET | 100 | 3.7 |
03:43 ET | 1800 | 3.72 |
03:45 ET | 641 | 3.72 |
03:48 ET | 1018 | 3.73 |
03:50 ET | 200 | 3.73 |
03:52 ET | 100 | 3.73 |
03:54 ET | 100 | 3.73 |
03:56 ET | 400 | 3.75 |
03:57 ET | 3500 | 3.76 |
03:59 ET | 5587 | 3.73 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Prelude Therapeutics Inc | 204.9M | -2.0x | --- |
Zura Bio Ltd | 204.0M | -1.1x | --- |
Omeros Corp | 203.4M | -1.3x | --- |
Acumen Pharmaceuticals Inc | 201.9M | -3.1x | --- |
INmune Bio Inc | 198.0M | -6.0x | --- |
Ovid Therapeutics Inc | 212.4M | -4.0x | --- |
Prelude Therapeutics Incorporated is a clinical-stage fully integrated oncology company built on a foundation of drug discovery to deliver novel precision cancer medicines to underserved patients. It has developed a diverse pipeline consisting of multiple distinct programs: kinases, targeted protein degraders, and precision antibody drug conjugates. Its product candidates include PRT3789, PRT2527 and PRT3645. PRT3789 is a highly selective degrader of SMARCA2 protein, which along with SMARCA4, controls gene regulation through chromatin remodeling. Its CDK9 program is an essential regulator of cancer-promoting transcriptional programs, including those driven by MCL1, MYC and MYB. PRT3645 is a brain and tissue penetrant molecule that potently targets CDK4/6 with a biased selectivity for CDK4. PRT2527 is designed to be a potent and selective CDK9 inhibitor. Its MCL1 candidate, PRT1419, is designed to be a potent and selective inhibitor of the anti-apoptotic protein, MCL1.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $204.9M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 54.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.54 |
EPS | $-1.88 |
Book Value | $4.32 |
P/E Ratio | -2.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.